A5032132615- Multiple Myeloma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- MRI in cancer diagnosis
- Cancer Treatment and Pharmacology
- Silicon Carbide Semiconductor Technologies
- Cutaneous lymphoproliferative disorders research
- Glioma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Chronic Myeloid Leukemia Treatments
Center for Discovery
2024-2025
Hackensack Meridian Health
2025
Hackensack University Medical Center
2023
Introduction Brain tumors pose significant diagnostic and therapeutic challenges due to their diverse treatment responses complex imaging characteristics. Traditional MRI techniques often struggle differentiate between tumor recurrence post-treatment changes such as pseudoprogression necrosis, highlighting the need for more accurate tools. Material Methods This retrospective study conducted at a single tertiary care center evaluated efficacy of Treatment Response Assessment Maps (TRAMs),...
e19523 Background: The approval of T-cell engagers (TCEs) for multiple myeloma (MM) has led to prolonged survival, yet baseline health disparities have been shown contribute inferior outcomes. TCEs changed the gold standard efficacy among patients with relapsed refractory MM (RRMM), response rates in heavily pretreated approaching 60-70% and median PFS ranging between 10 22 months. Access is not universal due REMS certification requirement CRS/ICANS management. We evaluated whether...
e19519 Background: T-cell engagers (TCE) have altered the therapeutic landscape, demonstrating response rates of 60-70% for patients with relapsed/refractory multiple myeloma (RRMM). Median progression free survival (PFS) among BCMA x CD3 TCEs teclistamab (Tec) and elranatamab (Elran) GPRC5D TCE talquetamab (Talq) ranges between 10 to 22 months. Yet, many RRMM treated in practice would been ineligible clinical trials due stringent inclusion criteria. Methods: A single-center retrospective...
Background and purpose The aim of this study was to determine the prevalence patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation (RT) plan (defined as <5 malignant lesions) may benefit from bridging RT prior CART. Materials methods This is single-center, retrospective R/R NHL received CART 2018 2022. Eligible had pre-apheresis...